
Projected most valuable R&D projects based on net present value 2022
This statistic displays the top pharmaceutical R&D projects based on net present value, as of December 2022. According to the source, the top R&D project was Daiichi Sankyos' monoclonal antibody for lung cancer treatment Datopotamab deruxtecan with a net present value of nearly 10 billion U.S. dollars at that time.